^
    CANCER:

    HER2 Negative Breast Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PARP inhibitor
    olaparib
    		0
    PARP inhibitor
    talazoparib
    ABT-888
    niraparib
    pamiparib
    alpelisib
    GDC-0032
    GDC-0077
    		1
    PIK3CA inhibitor
    HS-10352
    CYH33
    alpelisib + GDC-0032
    LX-086
    fulvestrant
    elacestrant
    SAR439859
    GDC-0927
    AZD9833
    		2
    Selective estrogen receptor degrader
    G1T48
    LX-039
    ZN-c5
    LY3484356
    D-0502
    SCR-6852
    CDK4 inhibitor + CDK6 inhibitor
    palbociclib
    abemaciclib
    ribociclib
    XZP 3287
    		3
    CDK4 inhibitor, CDK6 inhibitor
    dalpiciclib
    FCN-437
    palbociclib + ribociclib
    BPI-16350
    G1T38
    TQB3616
    Aromatase inhibitor
    exemestane
    		4
    Aromatase inhibitor
    anastrozole
    letrozole
    Aromatase inhibitor
    pembrolizumab
    nivolumab
    		5
    PD1 inhibitor
    toripalimab-tpzi
    nivolumab + toripalimab-tpzi
    cemiplimab-rwlc
    6
    mTOR inhibitor
    everolimus
    7
    PD-L1 inhibitor
    durvalumab
    atezolizumab
    8
    Estrogen receptor antagonist
    tamoxifen
    9
    DNA synthesis inhibitor
    gemcitabine
    nedaplatin
    10
    Selective estrogen receptor modulator
    toremifene
    lasofoxifene
    11
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    12
    Progesterone receptor agonist
    megestrol
    13
    Mitosis inhibitor
    vinorelbine
    14
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    paclitaxel oral
    15
    AKT inhibitor
    capivasertib
    16
    Thymidylate synthase inhibitor
    gimeracil / oteracil / tegafur
    capecitabine
    17
    Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel
    paclitaxel
    18
    PARG inhibitor
    IDE161
    19
    Estrogen receptor antagonist, Selective estrogen receptor degrader
    OP-1250
    GDC-9545
    anlotinib
    		20
    Multi-tyrosine kinase inhibitor
    TT-00420
    pazopanib
    cabozantinib capsule
    21
    Ubiquitin pathway modulator, Estrogen receptor alpha degrader
    ARV-471
    22
    Selective estrogen receptor α inhibitor
    H3B-6545
    23
    RANK ligand inhibitor
    denosumab
    24
    PD-L1 inhibitor, PARP inhibitor
    olaparib + durvalumab
    avelumab + talazoparib
    CT7001
    		25
    CDK7 inhibitor
    SY-5609
    Q901
    pegylated liposomal doxorubicin
    doxorubicin hydrochloride
    		26
    Topoisomerase II inhibitor
    pegylated liposomal doxorubicin
    epirubicin
    etoposide IV
    27
    HER2 inhibitor
    HER2 inhibitor
    trastuzumab
    28
    VEGFR-2 inhibitor
    rivoceranib
    29
    VEGF-A inhibitor
    bevacizumab
    30
    TTK inhibitor
    CFI-402257
    31
    eIF4A1 inhibitor, CDK4 inhibitor, CDK6 inhibitor
    abemaciclib + eFT226
    32
    VEGFR-2 inhibitor, PARP inhibitor
    rivoceranib + fluzoparib
    33
    Alkylating agent, DNA synthesis inhibitor
    cyclophosphamide + thiotepa
    34
    Tubulin inhibitor, Thymidylate synthase inhibitor
    capecitabine + DJ 927
    35
    IGF-1R inhibitor
    AMG 479
    36
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    37
    CXCR4 antagonist
    POL 6326
    E7389-LF
    		38
    Microtubule inhibitor
    cabazitaxel
    ixabepilone
    PI3K inhibitor
    		39
    PI3K inhibitor
    AN2025
    GDC-0941
    40
    ATR inhibitor, PARP inhibitor
    olaparib + AZD6738
    41
    VEGF-A inhibitor, PD1 inhibitor
    nivolumab + bevacizumab
    42
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    43
    PI3K inhibitor, AKT inhibitor
    RG7440
    letrozole + SAR439859
    		44
    Aromatase inhibitor, Selective estrogen receptor degrader
    fulvestrant + letrozole
    fulvestrant + anastrozole
    ABSK091
    		45
    FGFR inhibitor
    futibatinib
    E7090
    46
    CDK2 inhibitor
    PF-07104091
    BLU-222
    47
    IAP inhibitor
    APG-1387
    48
    PARP7 inhibitor
    RBN-2397
    49
    HER2 inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + tucatinib
    trastuzumab + abemaciclib
    50
    APC activator
    eftilagimod alpha
    51
    Tubulin polymerization promoter, Bcl2 inhibitor, Tubulin inhibitor
    carboplatin + albumin-bound paclitaxel
    52
    Wnt signalling pathway inhibitor
    OMP-18R5
    53
    ATR inhibitor
    BAY 1895344
    54
    Microtubule inhibitor, LY6E-targeted antibody-drug conjugate
    DLYE5953A
    55
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + non-pegylated liposomal doxorubicin
    56
    Microtubule inhibitor, Notch3-targeted antibody-drug conjugate
    PF-06650808
    57
    Selective estrogen receptor covalent antagonist
    HRS8807
    58
    mTOR inhibitor, Selective estrogen receptor degrader
    everolimus + LY3484356
    59
    PIK3CA inhibitor, Selective estrogen receptor degrader
    alpelisib + LY3484356
    60
    CDK4 inhibitor, CDK6 inhibitor, Multi-tyrosine kinase inhibitor
    dalpiciclib + SHR 1020
    61
    PLK4 inhibitor
    CFI-400945
    62
    Apoptosis stimulant
    pelareorep
    63
    Topoisomerase I inhibitor
    DAN-222
    64
    VEGF-A inhibitor, HER2 inhibitor
    bevacizumab + trastuzumab
    65
    KAT6 inhibitor
    PF-07248144
    ISM5043
    66
    Thymidine phosphorylase inhibitor
    trifluridine / tipiracil
    67
    Tubulin polymerization inhibitor, Thymidylate synthase inhibitor
    capecitabine + vinorelbine tartrate
    68
    Selective estrogen receptor degrader, AKT inhibitor
    capivasertib + AZD9833
    69
    Androgen receptor agonist
    CR 1477
    70
    Aurora kinase A inhibitor
    MLN8237
    71
    AKT inhibitor, p70S6K inhibitor
    LY2780301
    72
    pan-AKT inhibitor
    LAE002
    73
    ERN1 inhibitor
    ORIN1001
    74
    Selective androgen receptor modulator
    EP0062
    75
    Alkylating agent, Thymidylate synthase inhibitor
    capecitabine + D19466
    76
    Androgen receptor inhibitor, Selective estrogen receptor degrader
    enzalutamide capsule + fulvestrant
    77
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    78
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    79
    Tubulin inhibitor
    DJ 927
    80
    Estrogen receptor antagonist, mTOR inhibitor
    everolimus + tamoxifen
    81
    Alkylating agent
    cyclophosphamide
    82
    HDAC6 inhibitor
    ACY-1215
    83
    Microtubule inhibitor, CD166-targeted antibody-drug conjugate
    CX-2009
    TC
    TEC
    CaT
    FEC
    EC
    EC-P
    		84
    Chemotherapy
    CMF
    AC
    TAC
    GT
    GemCarbo
    VEX
    GC
    85
    PI3K inhibitor, mTOR inhibitor, AKT inhibitor
    mTOR inhibitor + PI3K inhibitor + AKT inhibitor
    86
    Immunotherapy, PARP inhibitor
    Immunotherapy + PARP inhibitor
    CDK4 inhibitor + CDK6 inhibitor + fulvestrant
    		87
    CDK4 inhibitor, CDK6 inhibitor, Selective estrogen receptor degrader
    abemaciclib + AZD9833
    palbociclib + SAR439859
    abemaciclib + LY3484356
    88
    PI3K inhibitor, Selective estrogen receptor degrader
    PI3K inhibitor + fulvestrant
    89
    Aromatase inhibitor, CDK4 inhibitor, CDK6 inhibitor
    Aromatase inhibitor + palbociclib
    letrozole + dalpiciclib
    90
    Aromatase inhibitor, mTOR inhibitor
    exemestane + mTOR inhibitor
    trastuzumab + neratinib
    		91
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    neratinib
    afatinib
    lapatinib + neratinib
    92
    CDK4 inhibitor, PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, CDK6 inhibitor, mTORC2 inhibitor
    palbociclib + PF-05212384
    93
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + lapatinib
    94
    Androgen receptor modulator, Selective androgen receptor modulator
    enobosarm
    95
    P-glycoprotein inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    oral paclitaxel / encequidar
    96
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Alkylating agent, Bcl2 inhibitor
    paclitaxel + cyclophosphamide + epirubicin
    97
    HER3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    U3-1402
    98
    PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    PF-05212384
    99
    Aromatase inhibitor, Thymidylate synthase inhibitor
    Aromatase inhibitor + capecitabine
    palbociclib + GDC-0077
    		100
    PIK3CA inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + GDC-0032
    palbociclib + alpelisib
    alpelisib + ribociclib
    101
    AKT3 inhibitor, AKT1 inhibitor, AKT inhibitor, p70S6K inhibitor
    DIACC3010
    102
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    carboplatin + docetaxel
    sacituzumab govitecan-hziy
    		103
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-1062a
    ESG401
    MK-2870
    104
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, CDK4 inhibitor, FGFR4 inhibitor, CDK6 inhibitor
    palbociclib + erdafitinib
    105
    PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, PARP inhibitor, mTORC2 inhibitor
    talazoparib + PF-05212384
    106
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor
    epirubicin + vinorelbine tartrate
    107
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    108
    FGFR inhibitor, VEGFR inhibitor, PDGFR α-β inhibitor, Tyrosine kinase inhibitor
    E 3810
    109
    PD-L1 inhibitor, GM-CSF agonist
    atezolizumab + talimogene laherparepvec
    110
    PD-L1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    durvalumab + fam-trastuzumab deruxtecan-nxki
    111
    CDK4 inhibitor, PI3K inhibitor, CDK6 inhibitor, AKT inhibitor
    palbociclib + RG7440
    112
    SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
    RP6530
    113
    CDK4 inhibitor, Selective estrogen receptor α inhibitor, CDK6 inhibitor
    palbociclib + H3B-6545
    114
    HER2 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab + ado-trastuzumab emtansine
    115
    Topoisomerase II inhibitor, Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel + epirubicin
    docetaxel + doxorubicin hydrochloride
    116
    PD-L1 inhibitor, PD1 inhibitor
    pembrolizumab + durvalumab
    117
    TLR9 agonist, PD1 inhibitor
    pembrolizumab + SD-101
    118
    IGF-2 inhibitor, CDK4 inhibitor, IGF1 inhibitor, CDK6 inhibitor
    abemaciclib + BI-836845
    119
    Bcr-abl tyrosine kinase inhibitor, CDK4 inhibitor, Src kinase inhibitor, CDK6 inhibitor
    palbociclib + bosutinib
    120
    Tubulin polymerization promoter, Apoptosis stimulant, Bcl2 inhibitor
    paclitaxel + pelareorep
    everolimus + ribociclib
    		121
    CDK4 inhibitor, mTOR inhibitor, CDK6 inhibitor
    everolimus + abemaciclib
    palbociclib + everolimus
    122
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    pembrolizumab + ado-trastuzumab emtansine
    123
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor, Thymidylate synthase inhibitor
    capecitabine + eribulin mesylate
    124
    CDK4 inhibitor, PI3K inhibitor, CDK6 inhibitor
    ribociclib + AN2025
    125
    VEGF-A inhibitor, Mitochondrial OXHPHOS inhibitor, mTOR inhibitor
    bevacizumab + ME-344
    126
    Topoisomerase II inhibitor, Alkylating agent, G-CSF stimulant, Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel + cyclophosphamide + epirubicin + pegfilgrastim
    127
    Aromatase inhibitor, mTOR inhibitor, GnRH agonist
    everolimus + letrozole + leuprolide acetate
    128
    Androgen receptor antagonist, Selective estrogen receptor degrader, TMPRSS2 inhibitor
    fulvestrant + GT0918
    129
    IGF-2 inhibitor, mTOR inhibitor, IGF1 inhibitor
    everolimus + BI-836845
    130
    PD1 inhibitor, GM-CSF agonist, CTLA4 inhibitor
    nivolumab + ipilimumab + talimogene laherparepvec
    131
    β-catenin inhibitor, Tubulin polymerization promoter, CBP inhibitor, Microtubule inhibitor
    carboplatin + eribulin mesylate
    132
    β-catenin inhibitor, DNA synthesis inhibitor, CBP inhibitor, Microtubule inhibitor
    gemcitabine + eribulin mesylate
    133
    PARP inhibitor, Topoisomerase I inhibitor
    niraparib + DAN-222
    134
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    135
    Estrogen receptor antagonist, CDK4 inhibitor, CDK6 inhibitor, Selective estrogen receptor degrader
    palbociclib + OP-1250
    136
    Ubiquitin pathway modulator, CDK4 inhibitor, CDK6 inhibitor, Estrogen receptor alpha degrader
    palbociclib + ARV-471
    137
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    PF-06873600
    		138
    CDK2 inhibitor, CDK4 inhibitor, CDK6 inhibitor
    ribociclib + BLU-222
    palbociclib + BLU-222
    139
    DNA replication inhibitor, Thymidylate synthase inhibitor
    capecitabine + bendamustine
    140
    PIK3CA inhibitor, Estrogen receptor antagonist, Selective estrogen receptor degrader
    GDC-9545 + GDC-0077
    141
    PIK3CA inhibitor, CDK4 inhibitor, CDK6 inhibitor, PI3Kδ inhibitor
    abemaciclib + copanlisib
    142
    CDK4 inhibitor, PD1 inhibitor, CDK6 inhibitor
    pembrolizumab + abemaciclib
    143
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    144
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    145
    HER2 inhibitor, HER4 inhibitor, HER2-targeted antibody-drug conjugate, EGFR inhibitor, Microtubule inhibitor
    ado-trastuzumab emtansine + pyrotinib
    146
    Microtubule stabilizer, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    docetaxel + capecitabine
    147
    BET inhibitor
    ZEN-3694
    148
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    149
    Microtubule stabilizer, Tubulin polymerization promoter, Alkylating agent
    docetaxel + cyclophosphamide
    150
    IDO inhibitor
    NLG8189
    151
    B7-H4-targeted antibody-drug conjugate, Tubulin inhibitor
    XMT-1660
    152
    Bone resorption factor inhibitor, Osteoclast inhibitor
    zoledronic acid
    153
    Bcl2 inhibitor
    venetoclax
    154
    HDAC inhibitor, XPO1 inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    selinexor + chidamide
    155
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    156
    KU70/KU80 inhibitor, PARP1 inhibitor, MRN complex inhibitor
    VIO-01
    157
    PI3Kα H1047R mutation inhibitor
    LOXO-783
    STX-478
    HR positive
    ER positive + PGR positive
    ESR1 mutation + HR positive
    ESR1 wild-type + HR positive
    HR negative
    ER positive + PGR negative
    HR positive + ER overexpression
    HR positive + APOBEC signature
    ER positive + TP53 mutation
    HER-2 negative
    HER-2 S310F
    HER-2 R896C
    HER-2 D769H
    HER-2 D769Y
    HER-2 L755S
    HER-2 L755_T759del
    HER-2 V777L
    HER-2 exon 19 deletion
    HER-2 exon 20 insertion
    HER-2 L755P
    HER-2 V842I
    HER-2 R678Q
    HER-2 P780ins
    HER-2 V773L
    HER-2 G309A
    HER-2 755_759del
    HER-2 L768S
    ER positive
    ESR1 mutation
    ER positive + ESR1 mutation
    ER Y537S
    ER Y537S + ER positive
    ER mutation
    ER D538G
    ER Y537N
    ER D538G + ER positive
    ER E380Q + ER positive
    ER Y537N + ER positive
    ER positive + ESR1 mutation + TP53 mutation
    ER negative
    PIK3CA exon 20 mutation + HR positive
    PIK3CA exon 9 mutation + HR positive
    PIK3CA exon 7 mutation + HR positive
    PIK3CA mutation + HR positive
    PIK3CA E542K + HR positive
    HR positive + PIK3CA exon 10 mutation
    HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G
    PIK3CA amplification + PIK3CA mutation + HR positive
    HR positive + PIK3CA H1047R
    HR positive + PIK3CA H1047R + ER D538G
    ESR1 mutation + PIK3CA mutation + HR positive
    BRCA2 mutation + HR positive
    HR negative + BRCA2 mutation
    HR positive + BRCA2 mutation
    BRCA2 mutation + ER positive + PGR positive
    BRCA1 mutation + HR positive
    HR negative + BRCA1 mutation
    HR positive + BRCA1 mutation
    HR negative + PD-L1 expression
    HR positive + PD-L1 expression
    PIK3CA H1047X
    PIK3CA E545X
    PIK3CA mutation
    PIK3CA mutation + HR negative
    PIK3CA E545K
    PIK3CA H1047R
    BRCA2 mutation
    PIK3CA mutation + ER positive
    ER positive + ESR1 mutation + PIK3CA mutation
    PIK3CA H1047R + PIK3CA D959N + ER E380Q
    FGFR1 amplification + HR positive
    FGFR1 overexpression + HR positive
    BRCA1 mutation
    BRCA1 mutation + HER-2 negative
    HIF1A overexpression
    BRCA mutation
    PD-L1 overexpression + ER positive
    ER positive + PGR negative + HER-2 negative
    AR positive + ER positive
    BACH1 overexpression
    BRCA2 mutation + HER-2 negative
    HR positive + HER-2 underexpression
    TMB-H
    BRCA wild-type
    FGFR1 amplification
    ER positive + FGFR1 amplification
    CXCR4 positive
    AKT1 mutation + HR positive
    CXCR4 expression
    AKT1 E17K + HR positive
    ER positive + ESR1 mutation + FGFR1 amplification
    HR positive + ERBB3 overexpression
    HR positive + ERBB3 underexpression
    FGFR1 overexpression
    NOTCH3 expression + ER positive + PGR positive
    PALB2 mutation
    ERBB3 G284R
    PGR positive
    CCND1 mutation + HR positive
    MTOR mutation + HR positive
    FANCL mutation
    CHEK2 mutation
    HR positive + BRAF V600E
    APOBEC3B deletion
    ER positive + HER-2 D769H + HER-2 V777L
    ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H
    IRS1-L
    IGFBP5-L
    FGF19 amplification + ER positive
    EGFR mutation + ER positive
    HR positive + TMB-L
    ATM expression + ATM T2333fs* + EGFR negative
    PD-L1 expression
    CCNE1 overexpression + PIK3CA muattion + ER positive
    FGF3 amplification + ER positive
    ER positive + FGFR3 amplification
    TYMS overexpression + HR positive
    FANCA mutation
    PTEN mutation
    ATR mutation
    High HDAC6 score + HR positive
    UNC13D mutation
    FGF4 amplification + ER positive
    RB1 mutation + HR positive
    CCND2 mutation + HR positive
    CAV1 overexpression + CAV2 overexpression
    FOXA1 expression + ER positive
    HR positive + TNFRSF11A overexpression
    RAD51 overexpression + HR positive
    PTEN mutation + HR positive
    BRCA2 mutation + ER positive
    HR positive + AR positive
    CDK4 mutation + HR positive
    MYC mutation + ER positive
    TFF1 overexpression + ER positive
    TFF3 overexpression + ER positive
    CCNE2 overexpression + PIK3CA mutation + ER positive
    PTEN deletion + ER positive
    ATM mutation
    CHEK1 mutation
    CDK12 mutation
    BRIP1 mutation
    BARD1 mutation
    RAD54L mutation
    RAD51D mutation
    RAD51C mutation
    RAD51B mutation
    ER positive + ESR1 mutation + CCND1 amplification
    PPP2R2A mutation
    CDKN1B mutation + HR positive
    ER positive + HER-2 negative
    HR positive + PTEN deletion
    HR positive + TMB-H
    HR positive + CCND1 amplification
    ER negative + HER-2 negative
    6-gene WNT pathway signature
    MHC-II expression
    HR positive + BRCA2 mutation + PALB2 mutation
    TP53 mutation
    HRD
    HR positive + BRIP1 amplification
    KRAS mutation + HR positive
    MLH3 overexpression + HR positive
    PCNA overexpression + HR positive
    CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive
    CETN2 overexpression + HR positive
    HR positive + AURKA mutation
    TP53 wild-type + ER positive
    HR positive + MYC mutation
    HR positive + MYC amplification
    HR positive + RB1 mutation
    HR positive + AURKA amplification
    HR positive + RAD51C amplification
    HR positive + TP53 mutation
    HR positive + BRCA1 mutation + PALB2 mutation
    ER positive + CDK6 overexpression
    HR positive + PLK1 overexpression
    TNFRSF1A overexpression + HR positive
    HDC overexpression + HR positive
    KRAS mutation + CDK9 overexpression + HR positive
    HR positive + CCNE1 overexpression
    AR negative